Back to all products

Microbial (Pro)TGase

Recombinant microbial (bacterial) transglutaminase


(MTG, recombinantly produced in E. coli, gene derived from Streptomyces mobaraensis)

Order
Quantity
Price
Status
25 U 270 € available
250 U (1 vial) 2140 € available
10 x 25 U 2140 € available
500 U (1 vial) 3750 € available
20 x 25 U 3750 € available


Documents
Art. No. T001
Synonym EC 2.3.2.13, MTG, BTG, BTGase, Protein-glutamine-γ-glutamyltransferase
Background info Transglutaminases are a family of enzymes that catalyze the posttranslational modification of proteins by inserting an isopeptide bond within or between polypeptide chains. These
enzymes catalyze the acyl transfer reaction between the γ-carboxyamide groups of peptidebound glutamine residues and a variety of primary amines, particularly the ε-amino group of lysine. The resulting crosslink is of great significance, since it is highly stable and also resistant to mechanical and proteolytic degradation.

Microbial Transglutaminase by Zedira
Molecular Weight 38,333 Da (Dispase-activated MTG with N-terminal sequence: FRAPDSDDR...)
Source Recombinantly produced in E. coli. Gene derived from Streptomyces mobaraensis.
Purity > 95 % (SDS-PAGE)
Specific Activity > 25 U/mg [One unit will catalyse the formation of 1 μmole of hydroxamate per min from Z-Gln-Gly-OH and hydroxylamine at pH 6.0 at 37°C, Grossowicz et al. (1950)]
Appearance White lyophilized solid.
Reagents The purified transglutaminase is lyophilized from 50 mM NaOAc pH 5.0 + 0.3 M NaCl.
Reconstitution Add the volume of H2O the protein is lyophilized from (see Certificate of Analysis) to the vial of lyophilized powder. Rotate vial gently until solid dissolves.
Reconstituted MTG solution might be turbid. However, MTG activity is not affected. In this case, centrifuge the solution and collect the supernatant.
After reconstitution, the solution should be stored frozen in working aliquots.
Application Labeling, immobilisation, conjugation and modification of proteins.
MTG can tolerate up to 10% DMSO in aqueous solutions without significant influence on its catalytic activity. A small activity loss of 4% was observed in the presence of 20% DMSO.
Storage Store at –20°C in working aliquots. Repeated freezing and thawing is not recommended.
Delivery is possible at ambient temperature.
Reference(s)

Spycher et al., ChemBioChem 2017, 18:1923-7
Steffen et al., J. Biol. Chem. 2017, 292:15622-35
Dennler et al., Chembiochem. 2015, 16:861-7
Dennler et al., Bioconjugate Chem. 2014, 25, 569-78
Kaufmann et al., Food Addit. Contam. Part. A 2012, 29:1364-73
Jeger et al., Angew. Chem. Int. Ed. Engl. 2010, 49:9995-7
Gianfrani et al., Gastroenterology 2007, 133:780-9
Pfleiderer et al., Microbiol. Res. 2005, 160:265-71
Ando et al., Agric. Biol. Chem. 1989, 53:2613-17
Pasternack et al., Eur. J. Biochem. 1998, 257:570-6
Grossowicz et al., J. Biol. Chem. 1950, 187, 111-25
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Process Change Notification: Transfer of the Pro-MTG production protocol from shaker flask to stirred tank fermenter (T001 (MTG) Process Change Notification.pdf).
Related Products A020 - Polyclonal antibody to bacterial protransglutaminase
A143 - Monoclonal antibody to microbial transglutaminase
A145 - Polyclonal antibody to bacterial transglutaminase (BTG, MTG)
C001 - Z-Gln-Gly-OH
C002 - Z-Gln-Gly-CAD-DNS
F015 - ZediXcite Fluorogenic MTG-Assay Kit
T153 - AndraconTM – recombinant microbial transglutaminase
Z009 - ZediXclusive Microbial Transglutaminase Assay Kit

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.
    All products

News  

  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
    Read more All news
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
    Read more All news
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
    Read more All news
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
    Read more All news
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
    Read more All news
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
    Read more All news
  • imagePress release: Zedira announces ISO 9001:2015 certification
    Read more All news

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
    Read more All posts
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
    Read more All posts
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering
    Read more All posts

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy

    All events